Alumis Inc. ALMS

Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population. Envudeucitinib is an investigational oral inhibitor of tyrosine kinase 2, or TYK2. The primary endpoint was the British Isles Lupus Assessment Group-based Composite Lupus Assessment, […]

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceSeptember 8-10, 2026, Boston, MAFireside chat: Tuesday, September 8, 2026 at 11:00 am ET Cantor Global Healthcare Conference September 9-11, 2026

Alumis stock presents a sharp disconnect between recent share price swings and what broad valuation checks suggest. After a very strong 1 year return, the company now screens as expensive on the wider metrics, even after a steep pullback following mixed trial news. Alumis has delivered a 121.2% return over the past year, which puts extra focus on whether the current price already reflects much of the good news investors expect. The recent Phase 2b LUMUS trial setback in lupus, together with...

In early September 2026, Alumis reported that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet primary and secondary endpoints in the overall patient population, despite a favorable safety profile over 48 weeks. An important finding was that a prespecified subgroup of patients with a high interferon gene signature showed robust clinical responses, supporting Alumis’ plan to pursue biomarker-driven Phase 3 development and an NDA in...

Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses. That mixed trial readout has gone hand in hand with sharp share price volatility, with a 7 day share price return of down 56.18% and a 30 day share price return of down 60.38%. Alumis still shows a year to date share price return of 15.58% and a 1 year total...

Alumis (NasdaqGS: ALMS) reported that its lead drug envudeucitinib did not meet primary or secondary endpoints in a Phase 2b lupus trial. The company highlighted strong efficacy and safety signals in a genetically defined IFNGS high subgroup of lupus patients within the study. Alumis plans to continue developing envudeucitinib and discuss potential regulatory paths for broader immune mediated indications based on the subgroup data. This update on Alumis shows how targeted drug development...

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a "Notice of

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th

Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitini

The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.

Tesla trades lower even as investors anticipate the potential entry of Cybercab into the company’s fleet of self-driving cabs.

Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage trial.

Alumis Inc. (Nasdaq: ALMS) said its Phase 2b LUMUS trial evaluating envudeucitinib in patients with moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary or secondary endpoints in the overall study population.

– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE – – Pharmacodynamic data substantiate envudeucitinib’s potential in interferon-driven immune-mediated diseases – – Envudeucitinib was generally well tolerated with no new safety signals observed – – Alumis remains on track to submit an NDA

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.